troglitazone has been researched along with Cushing Syndrome in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After evaluating a patient who appeared to have a falsely abnormal response to the dexamethasone suppression test while taking troglitazone, we examined the effects of troglitazone on the activity of hepatic CYP3A4 and the screening tests for Cushing's syndrome." | 3.72 | Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. ( Dimaraki, EV; Jaffe, CA, 2003) |
| "Troglitazone (TGZ) treatment, beginning at 6 weeks of age, prevented the hyperglycemia, the hyperlipidemia, and the increase in 11beta-HSD-1." | 1.32 | Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. ( Agarwal, AK; Duplomb, L; Lee, Y; Park, BH; Takaishi, K; Unger, RH; Wang, MY, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dimaraki, EV | 1 |
| Jaffe, CA | 1 |
| Duplomb, L | 1 |
| Lee, Y | 1 |
| Wang, MY | 1 |
| Park, BH | 1 |
| Takaishi, K | 1 |
| Agarwal, AK | 1 |
| Unger, RH | 1 |
| Iwasaki, Y | 1 |
| Takayasu, S | 1 |
| Nishiyama, M | 1 |
| Tsugita, M | 1 |
| Taguchi, T | 1 |
| Asai, M | 1 |
| Yoshida, M | 1 |
| Kambayashi, M | 1 |
| Hashimoto, K | 1 |
3 other studies available for troglitazone and Cushing Syndrome
| Article | Year |
|---|---|
Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test.
Topics: Adult; Anti-Inflammatory Agents; Breath Tests; Chromans; Corticosterone; Cushing Syndrome; Cytochrom | 2003 |
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Animals, Genetically Modified; Blotting, Weste | 2004 |
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Anticholesteremic Agents; Base Sequence; Cell | 2008 |